Health experts are now saying that monkeypox may potentially cause heart damage in some patients, according to a case study.
A 31-year-old gay man from Australia who had been diagnosed with monkeypox developed acute myocarditis days after the eruption of skin lesions, according to the study published in the JACC: Case Reports.
The study was titled, “Acute Myocarditis – a new manifestation of Monkeypox Infection?” and was a journal pre-proof, meaning it had been peer reviewed and accepted for publication by the Editorial Board.
From the study:
A 31-year-old male presented to the clinic with a 5-day history of malaise, myalgias and fever followed by the eruption of multiple swollen and umbilicated cutaneous lesions on his face, hands, and genitalia. He denied any other symptoms. Monkeypox infection was confirmed by a positive PC assay of a swab sample from a skin lesion.
Three days later, the patient returned to the emergency department with chest tightness radiating to the left upper extremity that awoke him during the night.
On physical examination, he displayed several skin vesicles and pustules on his face, wrists, thighs (Figure 1), and genitalia, with one ulcerated lesion on his penis accompanied by painful swelling of the foreskin and glans and lymphadenopathy in the left inguinal area. The patient was afebrile and hemodynamically stable. Cardiopulmonary auscultation and the
The lead author of the study, Dr. Ana Isabel Pinho, said “this case highlights cardiac involvement as a potential complication associated with
“We believe that reporting this potential causal relationship can raise more awareness of the scientific community and health professionals for acute myocarditis as a possible complication associated with Monkeypox and might be helpful for close monitoring of affected patients for further recognition of other complications in the future,” she stated.
Since the discovery of monkeypox, not a single instance of myocarditis has been reported until this day. The first case of human monkeypox was identified in a 9-month-old boy in the Democratic Republic of the Congo (DRC) in 1970, according to WHO.
Even CDC said that “infections with the type of monkeypox virus identified in this outbreak are rarely fatal. Over 99% of people who get this form of the disease are likely to survive. However, people with weakened immune systems, children under 8 years of age, people with a history of eczema, and people who are pregnant or breastfeeding may be more likely to get seriously ill or die.”
Since the promotion of mRNA COVID-19 vaccinations, myocarditis and pericarditis cases have risen globally.
CDC stated: “In April 2021, increased cases of myocarditis and pericarditis were reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna). Data from multiple studies show a rare risk for myocarditis and/or pericarditis following receipt of mRNA COVID-19 vaccines. These rare cases of myocarditis or pericarditis have occurred most frequently in adolescent and young adult males, ages 16 years and older, within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna).”
VAERS reported 51,879 cases of myocarditis and pericarditis through August 26, 2022.